JP2021512917A5 - - Google Patents

Info

Publication number
JP2021512917A5
JP2021512917A5 JP2020542801A JP2020542801A JP2021512917A5 JP 2021512917 A5 JP2021512917 A5 JP 2021512917A5 JP 2020542801 A JP2020542801 A JP 2020542801A JP 2020542801 A JP2020542801 A JP 2020542801A JP 2021512917 A5 JP2021512917 A5 JP 2021512917A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
once
weeks
composition according
nemolizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542801A
Other languages
English (en)
Japanese (ja)
Other versions
JP7777921B2 (ja
JP2021512917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/051051 external-priority patent/WO2019155427A1/en
Publication of JP2021512917A publication Critical patent/JP2021512917A/ja
Publication of JP2021512917A5 publication Critical patent/JP2021512917A5/ja
Priority to JP2023155476A priority Critical patent/JP2023182632A/ja
Priority to JP2025151311A priority patent/JP2025176134A/ja
Application granted granted Critical
Publication of JP7777921B2 publication Critical patent/JP7777921B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542801A 2018-02-09 2019-02-08 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ Active JP7777921B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023155476A JP2023182632A (ja) 2018-02-09 2023-09-21 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
JP2025151311A JP2025176134A (ja) 2018-02-09 2025-09-11 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
US62/628,714 2018-02-09
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023155476A Division JP2023182632A (ja) 2018-02-09 2023-09-21 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
JP2025151311A Division JP2025176134A (ja) 2018-02-09 2025-09-11 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ

Publications (3)

Publication Number Publication Date
JP2021512917A JP2021512917A (ja) 2021-05-20
JP2021512917A5 true JP2021512917A5 (cg-RX-API-DMAC7.html) 2022-02-15
JP7777921B2 JP7777921B2 (ja) 2025-12-01

Family

ID=65729402

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020542801A Active JP7777921B2 (ja) 2018-02-09 2019-02-08 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
JP2023155476A Pending JP2023182632A (ja) 2018-02-09 2023-09-21 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
JP2025151311A Pending JP2025176134A (ja) 2018-02-09 2025-09-11 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023155476A Pending JP2023182632A (ja) 2018-02-09 2023-09-21 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
JP2025151311A Pending JP2025176134A (ja) 2018-02-09 2025-09-11 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ

Country Status (23)

Country Link
US (2) US12435147B2 (cg-RX-API-DMAC7.html)
EP (2) EP4644424A3 (cg-RX-API-DMAC7.html)
JP (3) JP7777921B2 (cg-RX-API-DMAC7.html)
CN (1) CN112040976A (cg-RX-API-DMAC7.html)
AU (2) AU2019219608B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016144A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090062A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002050A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749353T3 (cg-RX-API-DMAC7.html)
ES (1) ES3049513T3 (cg-RX-API-DMAC7.html)
FI (1) FI3749353T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251101T1 (cg-RX-API-DMAC7.html)
IL (1) IL276524A (cg-RX-API-DMAC7.html)
LT (1) LT3749353T (cg-RX-API-DMAC7.html)
MX (1) MX2020008193A (cg-RX-API-DMAC7.html)
PH (1) PH12020551185A1 (cg-RX-API-DMAC7.html)
PL (1) PL3749353T3 (cg-RX-API-DMAC7.html)
PT (1) PT3749353T (cg-RX-API-DMAC7.html)
RU (1) RU2758378C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007558YA (cg-RX-API-DMAC7.html)
SI (1) SI3749353T1 (cg-RX-API-DMAC7.html)
TW (2) TWI856006B (cg-RX-API-DMAC7.html)
WO (1) WO2019155427A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535464A (zh) * 2023-11-02 2025-09-16 日商丸寶股份有限公司 醫藥組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
FI3284480T3 (fi) * 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2017093857A1 (en) * 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions

Similar Documents

Publication Publication Date Title
JP2020521797A5 (cg-RX-API-DMAC7.html)
JP2015512406A5 (cg-RX-API-DMAC7.html)
SG195049A1 (en) Methods of treating multiple sclerosis and preserving and/or increasing myelin content
JP2004527551A5 (cg-RX-API-DMAC7.html)
Storms et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis
JP2018526412A5 (cg-RX-API-DMAC7.html)
KR20120050473A (ko) 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
IE61120B1 (en) The use of D-fenfluramine for the manufacture of medicaments for treating depression
JP2017508737A5 (cg-RX-API-DMAC7.html)
WO2011022633A3 (en) Method of threating cancer
MX2025012741A (es) Composiciones farmaceuticas orales
JP2023182632A5 (cg-RX-API-DMAC7.html)
US10548870B2 (en) Method for treating multiple sclerosis
JP2009538935A5 (cg-RX-API-DMAC7.html)
Arshad et al. Ischemic stroke and post-stroke depression: the role of agomelatine
EP3558378A1 (en) Low dose drug combinations for use in preventing and treating neuronal damage
WO2022265960A1 (en) Prevention and treatment of neuronal damage with pyridoindolobenz[b, d] azepine compositions
US6455553B1 (en) Method for treating a demyelinating condition
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
CN112437661A (zh) 苯甲酸或其盐用于预防或治疗抗n-甲基-d-天冬氨酸受体脑炎的用途
US20260091012A1 (en) Methods Of Treating Meduloblastoma With Thyroid Hormone
RU2283097C2 (ru) Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
RU2824607C2 (ru) 2-(имидазол-4-ил)-этанамид пентандиовой-1,5 кислоты или его фармацевтически приемлемая соль для лечения covid-19 и ее симптомов
WO2025264860A3 (en) Methods of treating post-covid airway disease
EA049313B1 (ru) Применение 2-(имидазол-4-ил)этанамид пентандиовой-1,5 кислоты для лечения covid-19